Sign in

    Fynn Scherzler • Deutsche Bank

    Fynn Scherzler's questions to Evotec SE (EVO) leadership

    Fynn Scherzler's questions to Evotec SE (EVO) leadership • Q2 2025

    Question

    Fynn Scherzler from Deutsche Bank sought clarity on the Just Evotec Biologics (JEP) business, including the revenue mix between production and licensing, the nature of non-Sandoz customer growth, and the potential revenue of a fully utilized JPOD facility.

    Answer

    CEO Christian Wojczewski stated that current deals are packaged offerings, but the company plans to monetize individual components like licensing more directly in the future. CFO Paul Hitchin added that recent non-Sandoz growth is predominantly from development and production revenue. Regarding facility value, Mr. Hitchin noted the ~$300M consideration for the Toulouse site is expected to exceed its current book value but did not confirm a direct revenue-to-CapEx correlation.

    Ask Fintool Equity Research AI

    Fynn Scherzler's questions to Evotec SE (EVO) leadership • Q1 2025

    Question

    Fynn Scherzler of Deutsche Bank sought clarification on the EBITDA development, asking about the magnitude of phasing in the Just-Evotec business and whether its absolute EBITDA could decline in Q2. He also asked for details on the remaining headcount reduction impact in Shared R&D during Q1 to better forecast Q2 performance.

    Answer

    Executive Paul Hitchin confirmed that while there was some timing-related overperformance in Just-Evotec's Q1, the segment remains on track with the full-year plan. Regarding cost savings, he explained that headcount reductions from the Cologne site closure and other measures occurred throughout Q1, with the full run-rate effect of these savings to become more visible in the coming quarters. CEO Christian Wojczewski emphasized that the overall full-year guidance remains unchanged.

    Ask Fintool Equity Research AI

    Fynn Scherzler's questions to Evotec SE (EVO) leadership • Q1 2025

    Question

    Fynn Scherzler sought clarity on the EBITDA phasing for the Just-Evotec Biologics business, asking if absolute EBITDA might decline in Q2. He also requested details on the remaining headcount reductions in Shared R&D to better understand the Q2 cost base.

    Answer

    CFO Paul Hitchin confirmed the full-year guidance remains firm and that Q1's outperformance in the Just-Evotec segment was partly due to timing, but the business remains on track for the year. He explained that headcount reductions occurred throughout Q1, and the full run-rate effect of all cost-saving measures will become more visible in the coming quarters.

    Ask Fintool Equity Research AI